A leader in global health
London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on provid...
Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pr...
Mr König joins to lead late-stage drug development company developing proprietary fixed dose combina...
For George Health, 2019 and 2020 were watershed years. Multiple investors stepped forward to complete a capital raise of $53 million to back George Health’s ‘profit with purpose’ vision: improving and lengthening people’s lives, boosting health system sustainability and generating strong financial returns.
Read our year in review in The George Institute’s Annual Report 2020.